Ipsen in the world. Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neurosciences and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €2.2 billion in 2018, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,700 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com.
Ipsen in Russia. Russian division of Ipsen has been present in Russia for more than 25 years. Currently, Ipsen portfolio in Russia includes products in Specialty Care (oncology, endocrinology, neurology, gynecology), in Aesthetic and in the Consumer HealthCare (gastro-enterology and neurology). About 300 Ipsen employees in Russia work in more than 30 cities of the country to improve the quality of patients’ life.
Russia heads the CIS cluster consisting of 10 countries.
